Home › NDC Lookup › RxCUI directory › RxCUI 349462

Frovatriptan 2.5 MG Oral Tablet — RxCUI 349462

RxNorm drug concept · Semantic clinical drug
RxCUI 349462 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI349462
Official nameFrovatriptan 2.5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asfrovatriptan (as frovatriptan succinate 3.91 MG) Oral Tablet; frovatriptan succinate 2.5 MG Oral Tablet
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)3,620 prescriptions · 26 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Frovatriptan: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Frovatriptan is a treatment you take once a migraine has already started — it's not a preventive medication. You take it at the onset of a migraine attack to relieve the headache a...
  • What exactly does frovatriptan do — does it prevent migraines or stop them?
  • Take it as soon as you recognize a migraine coming on. Swallow the tablet with a full glass of fluid — you can take it with or without food. If your headache goes away and then com...
  • When should I take it during a migraine attack?
📖 Read our full Frovatriptan guide →

🕸️ Concept Web — How Frovatriptan 2.5 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Frovatriptan 2.5 MG Oral Tablet RxCUI 349462

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Frovatriptan 228783
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Frova 322250
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Frovatriptan Oral Tablet 378697
    • Frovatriptan Oral Product 1156665
    • Frovatriptan Pill 1156666
    • Frovatriptan Oral Tablet [Frova] 369444
    • Frova Oral Product 1173955
    • Frova Pill 1173956
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Frovatriptan 2.5 MG 351048
    • Frovatriptan 2.5 MG Oral Tablet [Frova] 352058
    • Frovatriptan 2.5 MG [Frova] 575807

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Frovatriptan 2.5 MG SCDC · 351048
  • Frovatriptan Oral Tablet SCDF · 378697
  • Frovatriptan Oral Product SCDG · 1156665
  • Frovatriptan Pill SCDG · 1156666

Brand-Name Concepts

  • Frovatriptan 2.5 MG Oral Tablet [Frova] SBD · 352058
  • Frovatriptan 2.5 MG [Frova] SBDC · 575807
  • Frovatriptan Oral Tablet [Frova] SBDF · 369444
  • Frova Oral Product SBDG · 1173955
  • Frova Pill SBDG · 1173956
  • Frova BN · 322250

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 349462 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50742-0299-09 1 BLISTER PACK in 1 CARTON (50742-299-09) / 9 TABLET, FILM... FROVATRIPTAN Ingenus Pharmaceuticals, LLC 2022-07-22
68462-0694-97 1 BLISTER PACK in 1 CARTON (68462-694-97) / 9 TABLET, FILM... frovatriptan succinate Glenmark Pharmaceuticals Inc., USA 2016-03-11
69238-1539-09 1 BLISTER PACK in 1 CARTON (69238-1539-9) / 9 TABLET, FILM... Frovatriptan Amneal Pharmaceuticals NY LLC 2018-11-13
69315-0157-13 9 TABLET, FILM COATED in 1 CARTON (69315-157-13) FROVATRIPTAN SUCCINATE Leading Pharma, LLC 2026-02-28
Observed labelers: Amneal Pharmaceuticals NY LLC (1) · Glenmark Pharmaceuticals Inc., USA (1) · Ingenus Pharmaceuticals, LLC (1) · Leading Pharma, LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$3.2618
Range $3.2618–$3.2618 · middle 50% $3.2618–$3.2618 · 3 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.